About this item:

63 Views | 25 Downloads

Author Notes:

David J. Lefer, Ph.D., Cardiovascular Center of Excellence, Louisiana State University Health Science Center, 533 Bolivar Street, Clinical Sciences Research Building, Suite 408, New Orleans, LA 70112, (T) 504-568-2109 (F) 504-568-3247, dlefe1@lsuhsc.edu

Dr. David Lefer serves as scientific consultant for Sulfagenix Inc, a company focusing on developing H2S-based therapy for clinical use. Dr. Lefer also has stock in both NovoMedix and SAJE Pharma, biotech companies that are developing novel therapeutics for cardiovascular diseases. Other authors declare no conflict of interests.

Subjects:

Research Funding:

This work was supported by Grants from NIH National Heart, Lung, and Blood Institute (R01 HL146098, R01 HL146514, R01 HL137711) to DJL, (R01 HL151398) to DJL and MX, (R01 HL133167, R35 HL155651) to FNS, American Heart Association Postdoctoral Grant (20POST3520075) to ZL, and (18POST34020143) to TES.

Keywords:

  • Science & Technology
  • Life Sciences & Biomedicine
  • Cardiac & Cardiovascular Systems
  • Hematology
  • Peripheral Vascular Disease
  • Cardiovascular System & Cardiology
  • amino acids
  • branched-chain
  • cell death
  • heart failure
  • hydrogen sulfide
  • mitochondrial respiration
  • CHAIN AMINO-ACIDS
  • HYDROGEN-SULFIDE
  • 3-MERCAPTOPYRUVATE SULFURTRANSFERASE
  • SULFANE SULFUR
  • DISEASE
  • ENZYME

Mitochondrial H2S Regulates BCAA Catabolism in Heart Failure

Show all authors Show less authors

Journal Title:

CIRCULATION RESEARCH

Volume:

Volume 131, Number 3

Publisher:

, Pages 222-235

Type of Work:

Article | Post-print: After Peer Review

Abstract:

Background: Hydrogen sulfide (H2S) exerts mitochondria-specific actions that include the preservation of oxidative phosphorylation, biogenesis, and ATP synthesis, while inhibiting cell death. 3-MST (3-mercaptopyruvate sulfurtransferase) is a mitochondrial H2S-producing enzyme whose functions in the cardiovascular disease are not fully understood. In the current study, we investigated the effects of global 3-MST deficiency in the setting of pressure overload-induced heart failure. Methods: Human myocardial samples obtained from patients with heart failure undergoing cardiac surgeries were probed for 3-MST protein expression. 3-MST knockout mice and C57BL/6J wild-type mice were subjected to transverse aortic constriction to induce pressure overload heart failure with reduced ejection fraction. Cardiac structure and function, vascular reactivity, exercise performance, mitochondrial respiration, and ATP synthesis efficiency were assessed. In addition, untargeted metabolomics were utilized to identify key pathways altered by 3-MST deficiency. Results: Myocardial 3-MST was significantly reduced in patients with heart failure compared with nonfailing controls. 3-MST KO mice exhibited increased accumulation of branched-chain amino acids in the myocardium, which was associated with reduced mitochondrial respiration and ATP synthesis, exacerbated cardiac and vascular dysfunction, and worsened exercise performance following transverse aortic constriction. Restoring myocardial branched-chain amino acid catabolism with 3,6-dichlorobenzo1[b]thiophene-2-carboxylic acid (BT2) and administration of a potent H2S donor JK-1 ameliorates the detrimental effects of 3-MST deficiency in heart failure with reduced ejection fraction. Conclusions: Our data suggest that 3-MST derived mitochondrial H2S may play a regulatory role in branched-chain amino acid catabolism and mediate critical cardiovascular protection in heart failure.

Copyright information:

© American Heart Association, Inc. All rights reserved.

Export to EndNote